For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination r ...

The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...

If you purchased or acquired securities in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at ...

The latest figures on prostate cancer are shocking: it has officially overtaken breast cancer as the most commonly diagnosed ...

Investigators report that estradiol works as well as luteinizing hormone–releasing hormone agonists for testosterone suppression and have a much better side-effect profile.

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...

Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...

Transdermal estradiol patches may be an alternative to LHRHas when combined with ARPIs to treat mHSPC, researchers say.

PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.